The potential effectiveness of PVRIG blockade in CT26 colon cancer can be boosted to significantly reduce tumor burden by combined blockade with anti-PD-L1[26], suggesting that combinational therapies can be more effective [45]. The gene discussed is CD274; the disease is malignant colon neoplasm.